3,985 research outputs found
The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease.
Sickle cell disease (SCD) is an extremely heterogeneous disease that has been associated with global morbidity and early mortality. More effective and inexpensive therapies are needed. During the last five years, the landscape of the pharmacotherapy of SCD has changed dramatically. Currently, 54 drugs have been used or under consideration to use for the treatment of SCD. These fall into 3 categories: the first category includes the four drugs (Hydroxyurea, L-Glutamine, Crizanlizumab tmca and Voxelotor) that have been approved by the United States Food and Drug Administration (FDA) based on successful clinical trials. The second category includes 22 drugs that failed, discontinued or terminated for now and the third category includes 28 drugs that are actively being considered for the treatment of SCD. Crizanlizumab and Voxelotor are included in the first and third categories because they have been used in more than one trial. New therapies targeting multiple pathways in the complex pathophysiology of SCD have been achieved or are under continued investigation. The emerging trend seems to be the use of multimodal drugs (i.e. drugs that have different mechanisms of action) to treat SCD similar to the use of multiple chemotherapeutic agents to treat cancer
Of pools, oceans, and the Dead Sea.
In a comprehensive study in this issue of Blood, Carden and colleagues describe the importance of the tonicity of IV fluids used in the treatment of patients with sickle cell disease (SCD) during vaso-occlusive crises (VOCs). Hypertonic fluids decreased sickle red blood cell (sRBC) deformability, increased occlusion, and increased sRBC adhesion in microfluidic human microvasculature models. Hypotonic fluids decreased sRBC adhesion but prolonged sRBC transit time. Fluids with intermediate tonicities resulted in optimal changes that reduced the risk of vaso-occlusion. © 2017 by The American Society of Hematology
Comorbidities in aging patients with sickle cell disease.
Sickle cell disease (SCD) in general and sickle cell anemia in particular is a highly complex disorder both at the molecular and clinical levels. Although the molecular lesion is a single-point mutation, the sickle gene is pleiotropic in nature causing multiple phenotypic expressions that constitute the various complications of the disease. Moreover, despite the fact that SCD is a chronic malady, its manifestations are both acute and chronic. The former include, among other things, the recurrent vaso-occlusive crises (its hallmark) and acute chest syndrome. The chronic complications include most commonly avascular necrosis and leg ulcers. Currently, survival of patients with SCD has improved dramatically thanks to newborn screening, antibiotic prophylaxis, better vaccine, safer blood transfusion and the use of hydroxyurea. It is the advent of these therapies that improved the survival. This improvement, however, introduced a third dimension of the disease: comorbidities that occur in aging people in the general population. There is concern that the gain in survival may be offset by the comorbidities. Thus it is the purpose of this review to identify the comorbidities in the elderly with SCD and differentiate them from the basis disease to implement proper therapies so that better survival could be maintained
Drugs for preventing red blood cell dehydration in people with sickle cell disease.
BACKGROUND: Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells. These are rigid and may block blood vessels leading to acute painful crises and other complications. Recent research has focused on therapies to rehydrate the sickled cells by reducing the loss of water and ions from them. Little is known about the effectiveness and safety of such drugs. This is an updated version of a previously published review.
OBJECTIVES: To assess the relative risks and benefits of drugs to rehydrate sickled red blood cells.
SEARCH METHODS: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group\u27s Haemoglobinopathies Trials Register.Last search of the Group\u27s Trials Register: 28 November 2015.
SELECTION CRITERIA: Randomized or quasi-randomized controlled trials of drugs to rehydrate sickled red blood cells compared to placebo or an alternative treatment.
DATA COLLECTION AND ANALYSIS: Both authors independently selected studies for inclusion, assessed study quality and extracted data.
MAIN RESULTS: Of the 51 studies identified, three met the inclusion criteria. The first study tested the effectiveness of zinc sulphate to prevent sickle cell-related crises in a total of 145 participants and showed a significant reduction in painful crises over one and a half years, mean difference -2.83 (95% confidence interval -3.51 to -2.15). However, analysis was restricted due to limited statistical data. Changes to red cell parameters and blood counts were inconsistent. No serious adverse events were noted in the study.The second study was a Phase II dose-finding study of senicapoc (a Gardos channel blocker) compared to placebo. Compared to the placebo group the high dose senicapoc showed significant improvement in change in hemoglobin level, number and proportion of dense red blood cells, red blood cell count and indices and hematocrit. The results with low-dose senicapoc were similar to the high-dose senicapoc group but of lesser magnitude. There was no difference in the frequency of painful crises between the three groups. A subsequent Phase III study of senicapoc was terminated early since there was no difference observed between the treatment and control groups in the primary end point of painful crises.
AUTHORS\u27 CONCLUSIONS: While the results of zinc for reducing sickle-related crises are encouraging, larger and longer-term multicenter studies are needed to evaluate the effectiveness of this therapy for people with sickle cell disease.While the Phase II and the prematurely terminated phase III studies of senicapoc showed that the drug improved red cell survival (depending on dose), this did not lead to fewer painful crises.We will continue to run searches to identify any potentially relevant trials; however, we do not plan to update other sections of the review until new trials are published
Effective Theory For Quantum Spin System In Low Dimension - Beyond Long-Wavelength Limit
An effective theory for quantum spin system in low dimension is constructed
in the finite-q regime. It is shown that there are field configurations for
which Wess-Zumino term contributes to the partition functions as topological
term for ferromagnet as well as antiferromagnet in both one and two dimensional
lattice,in contrast to the long wave length regime.Comment: 8 pages (Latex), no figure
Physical realization and possible identification of topological excitations in quantum Heisenberg anti-ferromagnet on a two dimensional lattice
Physical spin configurations corresponding to topological excitations,
expected to be present in the XY limit of a quantum spin 1/2 Heisenberg
anti-ferromagnet, are probed on a two dimensional square lattice . Quantum
vortices (anti-vortices) are constructed in terms of coherent staggered spin
field components, as limiting case of meronic (anti-meronic) configurations .
The crucial role of the associated Wess-Zumino-like (WZ-like) term is
highlighted in our procedure . The time evolution equation of coherent spin
fields used in this analysis is obtained by applying variational principle on
the quantum Euclidean action corresponding to the Heisenberg anti-ferromagnet
on lattice . It is shown that the WZ-like term can distinguish between vortices
and anti-vortices only in a charge sector with odd topological charges. Our
formalism is distinctly different from the conventional approach for the
construction of quantum vortices (anti-vortices) .Comment: 21 pages, 5 figures, laTe
Spectral Properties of a Two Component and Two Temperature Advective Flow
Low angular momentum accretion flows very often have centrifugal pressure
supported standing shock waves which can accelerate flow particles. The
accelerated particles in turn emit synchrotron radiation in presence of
magnetic fields. Efficient cooling of the electrons reduces its temperature in
comparison to the protons. In this paper, we assume two temperature flows to
explore this property of shocks and present an example of the emitted radiation
spectrum.Comment: 4 pages, 2 figures To be published in the Proceedings of 10th Marcel
Grossman Meeting, Ed. R. Ruffini et al. (World Scientific: Singapore
- …